Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma

por Prado, C M M, Bekaii-Saab, T, Doyle, L A, Shrestha, S, Ghosh, S, Baracos, V E, Sawyer, M B
Publicado 2012

Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells.

por Doyle, L. A., Ross, D. D., Sridhara, R., Fojo, A. T., Kaufmann, S. H., Lee, E. J., Schiffer, C. A.
Publicado 1995

An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.

por Doyle, L. A., Ross, D. D., Ordonez, J. V., Yang, W., Gao, Y., Tong, Y., Belani, C. P., Gutheil, J. C.
Publicado 1995

Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma

por Naing, A, LoRusso, P, Fu, S, Hong, D, Chen, H X, Doyle, L A, Phan, A T, Habra, M A, Kurzrock, R
Publicado 2013

Multicenter Evaluation of BD Max Enteric Parasite Real-Time PCR Assay for Detection of Giardia duodenalis, Cryptosporidium hominis, Cryptosporidium parvum, and Entamoeba histolytic...

por Madison-Antenucci, S., Relich, R. F., Doyle, L., Espina, N., Fuller, D., Karchmer, T., Lainesse, A., Mortensen, J. E., Pancholi, P., Veros, W., Harrington, S. M.
Publicado 2016

A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium

por Lheureux, S, Oza, A M, Laurie, S A, Halford, R, Jonker, D, Chen, E, Keller, D, Bourade, V, Wang, L, Doyle, L, Siu, L L, Goel, R
Publicado 2015

A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma

por Ott, Patrick A., Hamilton, Anne, Jones, Amanda, Haas, Naomi, Shore, Tsiporah, Liddell, Sandra, Christos, Paul J., Doyle, L. Austin, Millward, Michael, Muggia, Franco M., Pavlick, Anna C.
Publicado 2010

Northern Ireland farm-level management factors for prolonged bovine tuberculosis herd breakdowns

por Doyle, L. P., Courcier, E. A., Gordon, A. W., O'Hagan, M. J. H., Johnston, P., McAleese, E., Buchanan, J. R., Stegeman, J. A., Menzies, F. D.
Publicado 2020

Northern Ireland farm-level management factors for recurrent bovine tuberculosis herd breakdowns

por Doyle, L. P., Courcier, E. A., Gordon, A. W., O'Hagan, M. J. H., Johnston, P., McAleese, E., Buchanan, J. R., Stegeman, J. A., Menzies, F. D.
Publicado 2022

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal...

por Lee, Elizabeth K., Tan-Wasielewski, Zhenying, Aghajanian, Carol, Coleman, Robert L., Curtis, Jennifer, Hirsch, Michelle S., Matulonis, Ursula A., Cantley, Lewis C., Mills, Gordon B., Doyle, L. Austin, Liu, Joyce F.
Publicado 2020

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours

por Wilky, B A, Rudek, M A, Ahmed, S, Laheru, D A, Cosgrove, D, Donehower, R C, Nelkin, B, Ball, D, Doyle, L A, Chen, H, Ye, X, Bigley, G, Womack, C, Azad, N S
Publicado 2015

Novel Human Insulin Isoforms and Cα-Peptide Product in Islets of Langerhans and Choroid Plexus

por Liu, Qing-Rong, Zhu, Min, Zhang, Pingbo, Mazucanti, Caio H., Huang, Nicholas S., Lang, Doyle L., Chen, Qinghua, Auluck, Pavan, Marenco, Stefano, O’Connell, Jennifer F., Ferrucci, Luigi, Chia, Chee W., Egan, Josephine M.
Publicado 2021

A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer

por Murphy, Adrian G., Zahurak, Marianna, Shah, Mirat, Weekes, Colin D., Hansen, Aaron, Siu, Lillian L., Spreafico, Anna, LoConte, Noelle, Anders, Nicole M., Miles, Tearra, Rudek, Michelle A., Doyle, L. Austin, Nelkin, Barry, Maitra, Anirban, Azad, Nilofer S.
Publicado 2020

Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors

por Koczywas, M, Frankel, P H, Synold, T W, Lenz, H-J, Mortimer, J E, El-Khoueiry, A B, Gandara, D R, Cristea, M C, Chung, V M, Lim, D, Reckamp, K L, Lau, D H, Doyle, L A, Ruel, C, Carroll, M I, Newman, E M
Publicado 2014

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

por Xing, Yan, Lin, Nancy U., Maurer, Matthew A., Chen, Huiqin, Mahvash, Armeen, Sahin, Aysegul, Akcakanat, Argun, Li, Yisheng, Abramson, Vandana, Litton, Jennifer, Chavez-MacGregor, Mariana, Valero, Vicente, Piha-Paul, Sarina A., Hong, David, Do, Kim-Anh, Tarco, Emily, Riall, Dianna, Eterovic, Agda Karina, Wulf, Gerburg M., Cantley, Lewis C., Mills, Gordon B., Doyle, L. Austin, Winer, Eric, Hortobagyi, Gabriel N., Gonzalez-Angulo, Ana Maria, Meric-Bernstam, Funda
Publicado 2019